Lung Cancer Dispatch
Follow
Find tag "nausea"
4.1K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Tesaro Summarizes Phase 3 Rolapitant Data Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and Provides an Update on Niraparib Development Strategy

Tesaro Summarizes Phase 3 Rolapitant Data Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and Provides an Update on Niraparib Development Strategy | Lung Cancer Dispatch | Scoop.it

"TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today announced that final results from three Phase 3 trials of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV), were presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago."


Editor's note: This story is about a drug called rolapitant that shows promise in preventing nausea and vomiting for patients receiving chemotherapy treatment.

Cancer Commons's insight:

Benzinga  |  Jun 1, 2014

more...
Cancer Commons's curator insight, June 2, 2014 4:08 PM

Benzinga  |  Jun 1, 2014

Cancer Commons's curator insight, June 2, 2014 4:08 PM

Benzinga  |  Jun 1, 2014

Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

When Cancer Care Is Too Much of a Good Thing

When Cancer Care Is Too Much of a Good Thing | Lung Cancer Dispatch | Scoop.it

Some routine cancer tests and treatments can do more harm than good. Based on clinical evidence, the American Society of Clinical Oncology highlights cancer care that should be curbed in an annual Top Five List. This year's recommendations include:

  • Not giving antinausea drugs at the beginning of chemotherapies that are only moderately likely to cause nausea;
  • Not treating breast cancers that have spread with combination chemotherapy—unless symptom relief is urgent;
  • Not monitoring for cancer recurrence with advanced imaging technologies—such as positron-emission tomography (PET), computed tomography (CT) and radionuclide bone scans—unless there are symptoms of cancer;
  • Not screening men for prostate cancer unless they are likely to live at least another 10 years; and
  • Not giving people targeted therapies unless their tumor has the specific genetic abnormality that is targeted.
Cancer Commons's insight:

ASCO Post│Oct 29, 2013

more...
Cancer Commons's curator insight, October 30, 2013 7:43 PM

ASCO Post│Oct 29, 2013

Cancer Commons's curator insight, November 1, 2013 3:04 PM

ASCO Post│Oct 29, 2013